Screening and Assessment of Carcinomas

Abstract

The present disclosure is related to systems and methods to be used as aids in the diagnosis of risk for carcinoma, lesions, or dysplasia by identifying cellular phenotype characteristics of cell samples, including percentage of mature squamous cells, presence or absence of nuclear actin in mature squamous cells, percentage of non-mature squamous cells, percentage of small round cells, percentage of white blood cells, and percentage of lone nuclei.

What is claimed is: 
     
         1 . A method of assessing disease in a subject comprising:
 identifying at least one cellular phenotype of one or more cells in a sample of the subject;   determining a cellular phenotype characteristic that is a percent of mature squamous cells of the sample that express nuclear actin based upon the identified cellular phenotype of the cells; and   using the cellular phenotype characteristic to assess a presence or severity of a carcinoma, lesion, or dysplasia in the subject.   
     
     
         2 . The method of  claim 1 , wherein the carcinoma, lesion or dysplasia is associated with oral cancer, lung cancer, esophageal cancer, colorectal cancer, cervical cancer, skin cancer, liver cancer, kidney cancer, and breast cancer. 
     
     
         3 . The method of  claim 1 , wherein the disease is selected from the group consisting of: oral cancer, potentially malignant oral lesion (PMOL), and oral epithelial dysplasia (OED). 
     
     
         4 . The method of  claim 1 , wherein the percent of mature squamous cells expressing nuclear actin between 10% and 100% indicates the presence of a carcinoma, lesion, or dysplasia in the subject. 
     
     
         5 . The method of  claim 1 , wherein the percent of mature squamous cells expressing nuclear actin below 10% indicates the absence of a carcinoma, lesion, or dysplasia in the subject. 
     
     
         6 . The method of  claim 1 , wherein the determining step further comprises one or more cellular phenotype characteristics selected from the group consisting of: percent of mature squamous cells, percent of non-mature squamous cells, percent of small round cells, percent of white blood cells, and percent of lone nuclei. 
     
     
         7 . The method of  claim 5 , further comprising:
 determining one or more morphological characteristics from individual cells of the sample, said morphological characteristics selected from nuclear area, cell area, cell circularity, cell aspect ratio, and cell roundness;   transmitting the one or more morphological characteristics to a computer; and   using the cellular phenotype characteristics and morphological characteristics to assess the disease in the subject.   
     
     
         8 . The method of  claim 5 , further comprising:
 determining one or more biomarker levels in cells of the sample, said biomarker selected from the group consisting of alpha V beta 6 (AVB6), Epidermal Growth Factor Receptor (EGFR), Ki67, Geminin, Mini Chromosome Maintenance protein (MCM2), beta catenin, EMPPRIN, CD147, Cofilin, Importin 9, Profilin, thymosin-β4, Wiskott-Aldrich syndrome protein (WASp), Arp2/3 complex, and formins;   transmitting the one or more biomarker levels to a computer; and   using the cellular phenotype characteristics and biomarker levels to assess the disease in the subject.   
     
     
         9 . The method of  claim 5 , further comprising:
 transmitting one or more demographic data of the subject to a computer, said demographic data selected from the group consisting of race, ethnicity, gender, age, alcohol intake, height, weight, body mass index, tobacco use and smoking status of the subject; and   using the cellular phenotype characteristics and biomarker levels to assess the disease in the subject.   
     
     
         10 . The method of  claim 1 , wherein the method allows for the distinguishing between at least: 1) normal, 2) benign lesions, 3) mild dysplasia, 4) moderate dysplasia, 5) severe dysplasia, and 6) carcinoma in situ/malignant lesion. 
     
     
         11 . The method of  claim 1 , further comprising calculating a risk score based upon the cellular phenotype characteristics. 
     
     
         12 . The method of  claim 10 , further comprising displaying the risk score on an output device. 
     
     
         13 . The method of  claim 10 , wherein said calculation is based on artificial neural nets, logistic regression, linear discriminate analysis, or random forests. 
     
     
         14 . The method of  claim 1 , further comprising transmitting the one or more cellular phenotype characteristics to a remote processor to be assessed by a pathologist.